Roche has entered into a definitive merger agreement for Roche to acquire Anadys Pharmaceuticals, Inc. for $230 million in cash. Anadys, based in San-Diego, CA, develops oral, small molecule therapeutics for the potential treatment of hepatitis C virus (HCV) infection. Anadys’ most advanced drug candidate, Setrobuvir (ANA598), is a direct-acting antiviral compound currently in a Phase II study in combination with Roche’s pegylated interferon (Pegasys) and ribavirin (Copegus). Jean-Jacques Garau...